Publications

Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V et al..  2017.  SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.. Cancer Cell. 31(3):436-451.

Boysen G, Barbieri CE, Prandi D, Blattner M, Chae S-S, Dahija A, Nataraj S, Huang D, Marotz C, Xu L et al..  2015.  SPOP mutation leads to genomic instability in prostate cancer.. Elife. 4

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM et al..  2013.  Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.. Eur Urol. 63(5):920-6.

Rubin MA.  2008.  Targeted therapy of cancer: new roles for pathologists--prostate cancer.. Mod Pathol. 21 Suppl 2:S44-55.

Svensson MA, Lafargue CJ, MacDonald TY, Pflueger D, Kitabayashi N, Santa-Cruz AM, Garsha KE, Sathyanarayana UG, Riley JP, Yun CS et al..  2011.  Testing mutual exclusivity of ETS rearranged prostate cancer.. Lab Invest. 91(3):404-12.

Barry M, Perner S, Demichelis F, Rubin MA.  2007.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.. Urology. 70(4):630-3.

Perner S, Mosquera J-M, Demichelis F, Hofer MD, Paris PL, Simko J, Collins C, Bismar TA, Chinnaiyan AM, De Marzo AM et al..  2007.  TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.. Am J Surg Pathol. 31(6):882-8.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al..  2006.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. Cancer Res. 66(17):8337-41.

Demichelis F, Fall K, Perner S, Andrén O, Schmidt F, Setlur SR, Hoshida Y, Mosquera J-M, Pawitan Y, Lee C et al..  2007.  TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.. Oncogene. 26(31):4596-9.

Park K, Dalton JT, Narayanan R, Barbieri CE, Hancock ML, Bostwick DG, Steiner MS, Rubin MA.  2014.  TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.. J Clin Oncol. 32(3):206-11.

Demichelis F, Rubin MA.  2007.  TMPRSS2-ETS fusion prostate cancer: biological and clinical implications.. J Clin Pathol. 60(11):1185-6.

Rubin MA.  2015.  Toward a prostate cancer precision medicine.. Urol Oncol. 33(2):73-4.

Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.

Rubin MA.  2004.  Using molecular markers to predict outcome.. J Urol. 172(5 Pt 2):S18-21;discussionS21-2.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.